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ABSTRACT 
The present study examined the associations between genetic variation in folate 
metabolism on the one hand and cognitive functioning and mood on the other in 
healthy individuals. Two independent population-based samples were used, including 
777 participants, aged 24-82 years, from the Maastricht Aging Study (MAAS); and 
818 participants, aged 50-70 years, from the Folic Acid and Carotid Intima-Media 
Thickness (FACIT) study. Thymidylate synthase (TS) 2R→3R and serine 
hydroxymethyltransferase (SHMT1) 1420C→T polymorphisms were determined in 
both populations. In addition, the 5,10-methylenetetrahydrofolate reductase (MTHFR) 
677C→T polymorphism was determined in the MAAS population. Cognitive 
performance was assessed in both populations using a neuropsychological test battery. 
In the MAAS population only, cognitive performance was retested after 12 years of 
follow-up (n = 612), and mood was measured at baseline (n = 772) and 12-year 
follow-up (n = 565) by means of the depression subscale of the Symptom Checklist 
90. We found that in both study populations, cognitive performance was not 
associated with TS 2R→3R or SHMT1 1420C→T polymorphisms at baseline, after 
correction for age, sex, and level of education. The MTHFR 677C→T polymorphism 
was not associated with cognitive performance in the MAAS population. None of the 
polymorphisms in the MAAS population were related to mood at baseline or over 12 
years. In conclusion, our findings do not support the involvement of genetic variation 
in folate metabolism in cognitive performance or mood in healthy individuals. 
 
Keywords: folate metabolism; MTHFR; TS; SHMT1; cognitive performance; 
depressed mood 
	  	   4 
1. Introduction 
 Due to an increasing life expectancy, Western societies will be facing a 
steadily rising proportion of older individuals in the next decades. As impairments in 
cognitive functioning and mood state are highly prevalent in the ageing population, it 
is of growing interest to identify the underlying biological mechanisms. 
Among the biological factors suggested to be involved in cognitive 
impairment and depressed mood is genetic variation in folate metabolism (Bjelland et 
al., 2003; Elkins et al., 2007). Genetically determined changes in the activity of 
enzymes that are involved in the folate-homocysteine cycle may contribute to 
disturbances in neurocognitive functioning by reducing the availability of methyl 
donors, such as S-adenosylmethionine, for methylation processes that play an 
essential role in neurotransmitter and phospholipid metabolism, stabilization of 
myelin, and regulation of gene expression (Fuso et al., 2005; Tchantchou et al., 2006). 
For example, the common 677C→T mutation of the gene encoding 5,10-
methylenetetrahydrofolate reductase (MTHFR)a, which is associated with reduced 
enzyme activity, may lead to a decreased methylation capacity (Castro et al., 2004) 
(Figure 1). This polymorphism has been implicated in age-related cognitive decline 
and depressed mood, although results from population-based studies have yielded 
conflicting results. Whereas a number of studies have not found any relationship 
between the MTHFR 677C→T polymorphism and cognitive performance (Almeida et 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  a	  Abbreviations: APOE, apolipoprotein E; CST, Concept Shifting Test; FACIT, Folic 
Acid and Carotid Intima-Media Thickness study; LDST, Letter-Digit Substitution 
Test; MAAS, Maastricht Aging Study; MTHFR, 5,10-methylenetetrahydrofolate 
reductase; SCLdep, depression subscale of the Symptom Checklist 90; SHMT1, serine 
hydroxymethyltransferase; Str, speed on subtask of the Stroop Color-Word 
Interference Test; TS, thymidylate synthase; WLT, Visual Verbal Word Learning 
Task; WLTdr, delayed recall score of the Visual Verbal Word Learning Task; 
WLTmax, maximum score of the Visual Verbal Word Learning Task; WLTtot, total 
score on the Visual Verbal Word Learning Task.	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al., 2005; Bathum et al., 2007; De Lau et al., 2010; Gussekloo et al., 1999; Visscher et 
al., 2003) or depressive symptoms (Almeida et al., 2005; Gaysina et al., 2008). several 
other studies have reported that the MTHFR 677TT genotype was predictive of 
decreased cognitive functioning (Elkins et al., 2007), greater age-related cognitive 
decline (Elkins et al., 2007), clinically diagnosed depression (Hickie et al., 2001; 
Kelly et al., 2004), or depressive symptoms as observed in the general population 
(Bjelland et al., 2003).  
In contrast to the above-mentioned studies, we previously found that 
individuals carrying the MTHFR 677TT genotype showed better cognitive 
performance than CC homozygotes or CT heterozygotes in a large sample of older 
adults (Durga et al., 2006). We speculated that these positive effects might be related 
to a shift in the distribution of folate derivatives from methylated folates to formylated 
folates (Bagley and Selhub, 1998), which favors DNA synthesis and repair (Skibola et 
al., 2002) (Figure 1).  
Evidence for a clinical effect of the MTHFR 677C→T polymorphism has been 
provided by epidemiological studies reporting a decreased risk of colon cancer in TT 
homozygotes (Férnandez-Peralta et al., 2010; Taioli et al., 2009), which has been 
suggested to be related to increased DNA synthesis and repair (Blount et al., 1997). 
Interestingly, as both increased DNA damage and deficient DNA repair processes 
have been implicated in cognitive disorders, such as Mild Cognitive Impairment and 
Alzheimer’s disease (Coppedè and Migliore, 2009), it is reasonable to hypothesize 
that the MTHFR 677TT genotype might also exert a protective effect on cognitive 
functioning. 
DNA synthesis and fidelity may also be influenced by mutations in the gene 
encoding the enzyme thymidylate synthase (TS), which plays a critical role in 
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preventing chromosomal damage by lowering the incorporation of the abnormal 
nucleotide uracil in DNA (Horie et al., 1995). The presence of a triple versus double 
tandem repeat sequence in the regulatory region of the TS gene enhances its 
expression, thereby increasing DNA synthesis and repair (Horie et al., 1995). In 
addition, the 1420C→T polymorphism of the serine hydroxymethyltransferase 
(SHMT1) gene may result in a lower availability of folate derivatives for DNA 
synthesis (Hishida et al., 2003). Similar to the MTHFR 677TT genotype, both TS 3R 
and SHMT1 1420T variants have been associated with a reduced cancer risk (Hishida 
et al., 2003; Skibola et al., 2002).  
On the functional level, the MTHFR 677C→T, TS 2R→3R, and SHMT1 
1420C→T polymorphisms may be hypothesized to affect cognitive performance and 
mood state by influencing the fate of methyl donors. However, the associations 
between the TS and SHMT1 polymorphisms and cognitive functioning or mood have 
not yet been investigated. Therefore, the aim of the present study was to examine the 
associations between the MTHFR 677C→T, TS 2R→3R, and SHMT1 1420C→T 
polymorphisms on the one hand and cognitive functioning and mood on the other in 
healthy individuals. 
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2. Methods 
2.1. Participants 
The present study was carried out using data from two studies, the population-based 
Maastricht Aging Study (MAAS) and the Folic Acid and Carotid Intima-Media 
Thickness (FACIT) study. MAAS is a longitudinal research program investigating the 
determinants and consequences of cognitive aging (Jolles et al., 1995). Participants 
were randomly drawn from a register of family practices in the south of the 
Netherlands. Medically verified exclusion criteria at baseline were chronic 
neurological pathology, psychiatric disorders, mental retardation, and psychotropic 
drug use. The study population consisted of 1,823 participants, aged 24-81 years at 
baseline, and comprised four demographically identical panels, each stratified for age, 
sex, and level of occupational achievement. A detailed description of the MAAS 
study design can be found elsewhere (Jolles et al., 1995; Van Boxtel et al., 1998). 
Between 1993 and 1995 (baseline), all participants completed a general health and 
lifestyle questionnaire and underwent an extensive medical and neuropsychological 
examination. Participation in the blood sampling procedure was voluntary; venous 
blood samples for genotyping were collected for 779 individuals. Twelve years after 
the baseline assessments, the participants were invited to take part in the follow-up 
examinations. During follow-up, 167 participants had dropped out due to various 
reasons, including death, illness, and refusal to participate. Demographical, 
neuropsychological, and genetic information was available for 777 individuals at 
baseline and 612 individuals at 12-year follow-up.  
The FACIT study is a randomized, double-blind, placebo-controlled trial, 
originally designed to investigate the effects of 3-year folic acid supplementation on 
the risk of cardiovascular disease (Durga et al., 2007). The study population consisted 
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of 818 men and women from the Gelderland region in the Netherlands. Participants 
were recruited from blood bank registries as well as from municipal registries. At 
screening, individuals were included if between the ages of 50-70 years, and, 
specifically for women, had reached the menopause at least 2 years before. Exclusion 
criteria were plasma total homocysteine concentrations <13 µmol/L or >26 µmol/L, 
use of B-vitamin supplements or drugs that could affect atherosclerotic progression 
(e.g. lipid-lowering or hormone replacement therapies), or self-reported intestinal 
disease. Individuals with elevated homocysteine concentrations due to factors other 
than suboptimal folate concentrations, including serum vitamin B12 concentrations 
<200 pmol/L, self-reported medical diagnosis of renal or thyroid disorders, or self-
reported use of medications that influence folate metabolism, were also excluded. 
Venous blood samples were collected for genotyping at baseline. Cognitive 
functioning was assessed at baseline and after 3 years by means of a 
neuropsychological test battery.  
The MAAS study was approved by the Medical Ethics Committee of the 
Maastricht University Medical Centre, and the FACIT study by the Medical Ethics 
Committee of Wageningen University. Prior to enrolment all participants signed 
informed consent. 
 
2.2. Cognitive functioning 
Cognitive functioning was assessed by means of a neuropsychological test battery, 
consisting of five cognitive tests. The Visual Verbal Word Learning Task (WLT) was 
used to assess learning capacity, as well as recall and retrieval from long-term 
memory (Van der Elst et al., 2005). In three trials, fifteen commonly used 
monosyllabic words were visually presented in a fixed order at 2-s intervals. 
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Maximum and total immediate recall (WLTmax and WLTtot, respectively), as well as 
delayed recall after 20 min (WLTdr), were recorded.  
The Stroop Color-Word Interference Test was used to test selective attention 
and interference susceptibility (Van der Elst et al., 2006d). Three subtasks were 
presented on separate test sheets containing four rows of ten columns of color names 
or colored patches. Participants were required to read aloud color names printed in 
black (subtask I), name the color of colored patches (subtask II), and name the ink 
color of color names printed in an incongruous color (subtask III). The outcome 
parameters were speed on subtask I (Str1) and subtask III (Str3). 
The Concept Shifting Test (CST) is a test of behavioral planning and cognitive 
flexibility (Van der Elst et al., 2006b). Participants were asked to cross out sixteen 
items presented in small circles on a test sheet as fast as possible in the right order (1–
2–3–4 [subtask A], A–B–C–D [subtask B], 1–A–2–B [subtask C]). In a final subtask 
(subtask O), individuals were instructed to cross out empty circles as fast as possible, 
in order to measure general motor speed. The outcome parameters were speed on 
subtask A (CSTa), subtask B (CSTb), subtask C (CSTc), and subtask O (CST0). 
The Letter-Digit Substitution Test (LDST) was used to measure information 
processing speed and efficiency of operations in working memory (Van der Elst et al., 
2006c). Participants were asked to replace letters presented on a test sheet by their 
corresponding digits, as indicated by a key showing nine numbers paired with 
different letters. The total number of correct substitutions completed within 90 s was 
recorded.  
The Verbal Fluency Test measures the ability to recollect clusters of related 
words from encyclopedic memory (Van der Elst et al., 2006a). Participants were 
instructed to name as many animals as possible in 60 s. The outcome measure was the 
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total number of different animals named. 
 
2.2.1. Data reduction  
In order to limit the number of dependent variables and to improve the robustness of 
the underlying cognitive construct, the raw test scores of the WLT, the Stroop Color-
Word Interference Test, and the CST were clustered into three a-priori defined 
composite performance indices (Lezak et al., 2004). The raw test scores were 
transformed into Z-scores by subtracting the mean score from the individual test score 
and dividing this by the mean SD (Z = (x – mean)/SD). For the cross-sectional 
analyses, the means and SD’s of the baseline test scores were used to calculate the Z-
scores per test. For the longitudinal analyses in the MAAS population, the grand 
means and SD’s of the pooled measurements (i.e. baseline and 12-year follow-up) 
were used to calculate the Z-scores for both time points, thereby creating test scores 
referring to the same Z-distribution, which enabled the inclusion of both baseline and 
follow-up scores in one statistical model. The Z-scores were averaged, resulting in the 
following composite scores: memory ([ZWLTmax + ZWLTtot + ZWLTdr]/3), 
sensorimotor speed ([ZStr1 + ZCSTa + ZCSTb + ZCST0]/4), and complex speed 
([ZStr3 + ZCSTc]/2). The signs of the two speed scores were inverted in order to 
reflect above normal performance when positive, and below normal when negative. 
Cognitive performance on the domains of information processing speed and word 
fluency was represented by the Z-score of the LDST test and the Z-score of the Verbal 
Fluency Test, respectively. 
 
2.3. Mood 
In the MAAS population, mood was assessed at baseline and after 12 years of follow-
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up by means of the Dutch version of the depression subscale of the Symptom 
Checklist 90 (SCLdep), a multidimensional checklist for psychopathological 
complaints based on self-report (Arrindell and Ettema, 1986). The SCLdep consists of 
sixteen items, which are rated on a 5-point ordinal scale ranging from 1 (no 
complaints) to 5 (maximal complaints). Sum scores range from 16 to 80, with higher 
scores representing increased depressed mood. In total, 772 individuals completed the 
SCLdep at baseline, as well as 565 individuals at 12-year follow-up.  
 
2.4. Genotyping 
Genomic DNA was isolated from EDTA blood samples using an MN blood kit 
(Bioké, Leiden, The Netherlands). MTHFR 677C→T genotype was determined by 
polymerase chain reaction (PCR) with restriction fragment length polymorphism 
analysis with HinfI (Frosst et al., 1995). TS genotype was determined by PCR, 
followed by gel electrophoresis to show the presence of double (2R2R) or triple 
(3R3R) tandem repeats in the promotor region (Horie et al., 1995). SHMT1 1420C→T 
genotype was determined using fluorogenic probes in real-time PCR assay (Skibola et 
al., 2002). Apolipoprotein E (APOE) genotype was determined by PCR followed by 
restriction digestion with HhaI (Bekers et al., 2002).  
 
2.5. Blood measurements 
In the FACIT population, fasting venous blood samples were collected at baseline, 
directly processed, and stored at -80°C. Serum folate was measured using a 
chemiluminescent immunoassay (Immulite 2000, Diagnostic Products Corporation, 
Los Angeles, CA). Erythrocyte folate was determined in duplicate and the average 
was taken to reduce measurement error. Erythrocyte folate concentrations were 
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calculated by means of the following formula: (unadjusted erythrocyte 
folate/hematocrit) – ([1 – hematocrit]/hematocrit) × serum folate. Plasma total 
homocysteine was determined by high-performance liquid chromatography and 
fluorimetric detection, as described previously (Ubbink et al., 1991). 
 
2.6. Education 
Level of education was measured by classifying formal schooling according to the 
Dutch educational system (De Bie, 1987), and categorized into low, middle, or high, 
i.e. corresponding to primary education, junior vocational training, and senior 
vocational/academic training, respectively. 
 
2.7. Statistical analysis   
Normal probability plots were used to check whether the dependent variables were 
normally distributed. SCLdep scores showed a skewed distribution, which was 
corrected by log-transformation. Baseline data were used to assess the cross-sectional 
associations between the three genotypes and cognitive functioning or mood in both 
study populations. It should be noted that the cross-sectional relationship between 
MTHFR genotype and cognitive performance was not analyzed in the FACIT 
population, as these associations had been reported elsewhere (Durga et al., 2006). 
Univariate ANCOVA were performed for each polymorphism in relation to 
each of the five cognitive performance indices, as well as mood. The analyses were 
corrected for age, sex, and level of education in order to reduce residual variance in 
the outcome measures, thereby increasing statistical power. Longitudinal analyses 
were restricted to the MAAS population, as the follow-up of the FACIT study 
involved 3-year supplementation with folic acid, which may influence both the 
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phenotypic expression of the polymorphisms studied (Girelli et al., 1998) and 
cognitive performance (Durga et al., 2007). Power calculations showed that including 
only the placebo group (n = 413) in the longitudinal analyses would not yield 
sufficient statistical power. Repeated measures ANCOVA with time as a within-
subjects variable and genotype as between-subjects variable were used to investigate 
the longitudinal associations between each of the three genotypes and cognitive 
performance over 12 years of follow-up, which were represented by the time × 
genotype interaction. The analyses were adjusted for age, age2 (to control for non-
linear effects of age), sex, and level of education. Similar analyses were performed 
with mood as the dependent variable.  
In secondary analyses, we stratified both study populations by APOE E4 
carrier status (defined as E4+ or E4–, depending on the presence of at least one E4 
allele) to determine whether the cross-sectional and longitudinal associations between 
the genotypes and cognitive functioning differed between carriers and non-carriers of 
the APOE E4 allele, as APOE E4 carrier status may interact with a low folate status or 
high homocysteine levels in increasing individual susceptibility for cognitive 
impairment (Shea et al., 2004). In addition, the FACIT sample was stratified by folate 
status (low-normal: erythrocyte folate <501 nmol/L, and high-normal: erythrocyte 
folate ≥501 nmol/L) (Durga et al., 2006), as folate concentrations may influence 
phenotypic expression of the genotypes studied (Girelli et al., 1998). The MAAS 
sample was not stratified by folate status, as information on folate concentrations was 
not available.  
Homogeneity of error variances was ascertained by means of Levene’s test for 
equality of error variances. Hardy-Weinberg equilibrium was assessed using Chi-
square tests. The statistical power of the cross-sectional and longitudinal analyses to 
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detect small effects (f2 = 0.02) of each of the three polymorphisms on cognitive 
performance and mood in both populations was high, i.e. >0.90. Statistical differences 
were considered significant at p-values <0.05. All analyses were performed using 
SPSS 16.0 (SPSS Inc., Chicago, IL). 
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3. Results  
Table 1 summarizes the baseline characteristics of the participants in both study 
populations. The MTHFR, TS, and SHMT1 allele frequencies were in Hardy-
Weinberg equilibrium and were comparable to the frequencies reported in other 
healthy populations (Elkins et al., 2007; Skibola et al., 2002; Visscher et al., 2003).  
At baseline, none of the genetic polymorphisms were associated with 
cognitive performance on any of the domains measured in the MAAS population 
(Table 2) or the FACIT population (Table 3). In addition, the different genotypes did 
not show any relationship with mood in the MAAS population (Table 2).  
One sample t tests indicated that cognitive performance in the MAAS 
population significantly declined over the 12-year follow-up period on the domains of 
sensorimotor speed (mean change ± SD = -0.29 ± 0.64, p <0.001), complex speed 
(mean change ± SD = -0.31 ± 0.67, p <0.001), information processing speed (mean 
change ± SD = -0.14 ± 0.55, p <0.001), and word fluency (mean change ± SD = -0.21 
± 0.87, p <0.001). Memory performance significantly improved (mean change ± SD = 
0.32 ± 0.75, p <0.001), which is due to the effect of procedural learning. Depressive 
symptoms significantly increased over the 12-year follow-up period, as indicated by 
higher SCLdep scores (mean change ± SD = 1.42 ± 6.78, p <0.001). In the 
longitudinal analyses, we found no significant associations between the MTHFR 
677C→T, TS 2R→3R, and SHMT1 1420C→T polymorphisms on the one hand and 
cognitive functioning and mood over 12 years on the other, which was revealed by the 
absence of significant time × genotype interactions in repeated measures ANCOVA 
(Table 4).  
To examine whether folate status might influence the associations between the 
TS or SHMT1 polymorphisms and cognitive performance, the FACIT population was 
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stratified by erythrocyte folate concentration. The stratification procedure did not 
reveal any significant results (data not shown), suggesting that folate status did not 
modify the putative associations between the two genotypes and cognitive 
performance.  
Both study populations were stratified by APOE E4 allele carrier status to 
determine whether possession of the APOE E4 allele influenced the associations 
between the three genotypes and cognitive performance. The results of the cross-
sectional and longitudinal analyses in the MAAS sample did not differ between 
carriers and non-carriers of the APOE E4 allele (data not shown), indicating that this 
variable was no effect modifier in this study population. In the FACIT sample, 
however, the SHMT1 1420TT genotype was associated with decreased memory 
performance at baseline (mean ± SD = -0.33 ± 1.03) as compared with CC 
homozygotes (mean ± SD = 0.04 ± 0.90) and CT heterozygotes (mean ± SD = -0.04 ± 
0.96) in non-carriers (p = 0.015), but not in carriers of the APOE E4 allele (p = 
0.675). 
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4. Discussion 
The present study showed that the MTHFR 677C→T, TS 2R→3R, and SHMT1 
1420C→T polymorphisms were not related to cognitive performance or mood in two 
large samples of healthy individuals. The present findings are in line with other cross-
sectional studies reporting the lack of any significant associations between MTHFR 
genotype and cognitive performance in older individuals (Almeida et al., 2005; 
Bathum et al., 2007; De Lau et al., 2010; Gussekloo et al., 1999; Visscher et al., 
2003), and with a population-based study in 1,581 Danish nonagenarians showing no 
impact of the MTHFR 677TT genotype on cognitive decline over 5 years (Bathum et 
al., 2007).  
In contrast to the present findings, Elkins et al. (2007) found that the MTHFR 
677TT genotype was associated with decreased information processing speed, as well 
as greater annual cognitive decline as indicated by Mini-Mental State Examination 
score, in a US population-based sample of 6,653 older women. However, their 
longitudinal results should be interpreted with caution, as the Mini-Mental State 
Examination is a relatively crude indicator of cognitive functioning. Originally 
designed to screen for symptoms of cognitive impairment (Folstein et al., 1975), this 
test is fairly insensitive to individual variation in cognitive performance in healthy 
aging individuals.  
The present results on mood are in line with a number of studies that found no 
significant relationship between the MTHFR 677C→T polymorphism and depressive 
symptoms (Almeida et al., 2005; Gaysina et al., 2008). In contrast, the MTHFR 
677TT genotype was reported to be related to an increased risk of depression in a 
large population-based study of 5,948 older Norwegian individuals (Bjelland et al., 
2003), a case-control study of 78 older Australian patients with late-onset depression 
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and 22 healthy controls (Hickie et al., 2001), and a case-control study carried out in 
Northern Ireland, including 100 patients with major depressive disorder matched with 
89 controls (Kelly et al., 2004). An important methodological difference between the 
present study and most of the above-mentioned studies is that we did not use a 
dichotomous measure of depressive symptoms. Instead, we measured depressive 
symptoms on a continuous scale, which not only increased statistical power, but also 
allowed for the detection of subclinical depressive symptoms, which are highly 
prevalent in the general population (Kessler et al., 1997). Although the studies 
comparing depressed persons with non-depressed individuals suggest that the MTHFR 
677C→T polymorphism might increase the risk of depression, our results indicate 
that this polymorphism might not be related to subclinical depressive symptoms in the 
general population. Similar to our study, Almeida et al. (2005), who also used a 
continuous measurement of depressive symptoms, did not find any significant 
associations between MHTFR genotype and mood in a study sample of 240 
community-dwelling women.  
We previously found that the MTHFR 677TT genotype was associated with 
increased sensorimotor speed in the FACIT population (Durga et al., 2006). In the 
present study, we failed to replicate these findings in the MAAS population. These 
conflicting results could be attributable to differences in the age range of the two 
study populations. It might also be argued that the unequal sex distribution of the 
FACIT population might have contributed to the observed discrepancy in results. In 
addition, these contrasting findings might be related to the fact that, in contrast to the 
MAAS population, the FACIT population is not representative of the general 
population, as it included only individuals with plasma total homocysteine 
concentrations between 13 and 26 µmol/L. Thus, it cannot be ruled out that this 
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selection criterion might have biased the results obtained in the FACIT population. It 
should be noted, however, that it is unlikely that the lack of significant associations 
was due to insufficient statistical power, as our study had sufficient power to detect 
small associations in both study samples.  
In our previous study, we showed that the MTHFR 677C→T polymorphism 
was associated with increased complex speed in individuals with erythrocyte folate 
concentrations below the median (Durga et al., 2006). As folate status may influence 
phenotypic expression of the polymorphisms studied (Girelli et al., 1998; Religa et 
al., 2003), it cannot be ruled out that the lack of stratification by folate concentrations 
in the MAAS population might have obscured any potential associations between the 
MTHFR 677C→T polymorphism and cognitive performance. With respect to the TS 
2R→3R and SHMT1 1420C→T polymorphisms, however, it is not very likely that the 
null findings in the MAAS population may be accounted for by the lack of 
stratification by folate status, as the stratified analyses in the FACIT population 
suggest that folate status is not an effect modifier of the putative associations between 
these polymorphisms and cognitive performance.  
The lack of significant associations in the present study might be due to the 
possibility that more than one genetic polymorphism might need to be present in order 
to significantly influence cognitive performance. However, there were too few 
individuals homozygous for either all three mutations (n = 3), or two out of three 
mutations studied (n = 56), to yield sufficient statistical power for detecting potential 
associations within these subsamples. 
To investigate the possibility that an additional risk factor for cognitive 
impairment, such as APOE E4 carrier status (Caselli et al., 2009; Deary et al., 2002), 
must be present for cognitive effects of any of the genetic polymorphisms to become 
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apparent, we stratified our analyses by APOE E4 allele carrier status. In the FACIT 
sample, we found that the SHMT1 1420TT genotype was associated with decreased 
memory performance in non-carriers of the APOE E4 allele. In the MAAS population, 
however, results did not differ between carriers and non-carriers of the APOE E4 
allele. Although the present findings did not unequivocally support the hypothesis that 
APOE E4 carrier status may interact with MTHFR 677C→T, TS 2R→3R, or SHMT1 
1420C→T polymorphisms to influence cognitive functioning, they did suggest that 
the associations between the SHMT1 1420TT genotype and memory performance 
might differ between carriers and non-carriers of the APOE E4 allele. The biological 
mechanisms underlying such an interaction between the SHMT1 1420C→T 
polymorphism and APOE E4 carrier status remain to be identified. 
Our study had several strengths, such as the use of two large study 
populations, the measurement of three different genotypes related to folate 
metabolism, and the inclusion of 12-year longitudinal data on cognitive performance 
and mood. To our knowledge, our study was the first to explore the TS 2R→3R and 
SHMT1 1420C→T polymorphisms in relation to cognitive functioning and mood.  
Summarizing, the present study does not support the involvement of the 
MTHFR 677C→T, TS 2R→3R and SHMT1 1420C→T polymorphisms, which are 
known to affect enzyme activity in folate metabolism, on the one hand and cognitive 




In the present study, we did not find evidence for the involvement of the MTHFR 
677C→T, TS 2R→3R, or SHMT1 1420C→T polymorphisms in cognitive functioning 
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or mood state in healthy adults. Our findings do not support the hypothesis that 
genetically determined variation in the activity of enzymes that may influence 
methylation capacity and DNA fidelity might play a role in depressed mood or age-
related cognitive decline. 
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